Prot #UMCC 2017.026NU UM17I01: A Multi-Center Randomized Phase II Study of Nivolumab in Combination with Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
- Benson III, Al B (PD/PI)
Project: Research project